Good
Mostly Aligned
Patient Risk:
Low
Summary
The claim that COMBIVENT RESPIMAT is a fixed-dose combination inhaler containing ipratropium and albuterol is supported by the provided label excerpts (active ingredients) and is not contradicted. However, the claim does not specify that the dosing is fixed, and the provided excerpts are primarily about the active ingredients/combination rather than explicitly stating the phrase 'fixed-dose combination inhaler.'
Category Scores
Accurate Statements
Combivent is a brand of a fixed-dose combination inhaler that contains ipratropium and albuterol.
Label provided lists COMBIVENT RESPIMAT as having active ingredients ipratropium bromide and albuterol sulfate, delivered per actuation (20 mcg ipratropium bromide and 100 mcg albuterol per actuation).
Unsupported Statements
fixed-dose combination inhaler
The provided excerpts confirm it is a combination product (ipratropium + albuterol) with specified per-actuation doses, but the exact characterization 'fixed-dose combination inhaler' is not explicitly stated in the provided label text.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim is a product composition/identity statement and does not include dosing, contraindications, or safety instructions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Wording ('fixed-dose combination inhaler') not explicitly present in the provided label excerpts.
Suggested Improvement
Rephrase to match provided label language, e.g., 'COMBIVENT RESPIMAT contains ipratropium bromide and albuterol sulfate (delivered as specified microgram amounts per actuation).'